Hypothesis

In aging skeletal muscle, AGE‑mediated collagen crosslinks initially act as a proteostatic stopgap that preserves tissue architecture when chaperone and degradation systems falter. However, these persistent crosslinks alter matrix mechanics in a way that chronically activates integrin‑FAK signaling, driving nuclear YAP/TAZ accumulation and sustained upregulation of TIMP1/2. The resulting MMP/TIMP imbalance prevents matrix remodeling, locking the tissue in a stiff state that impairs satellite cell proliferation and promotes fibrosis. Thus, the maladaptive outcome stems not from the crosslinks themselves but from a feedback loop that suppresses proteolytic capacity.

Rationale

• Yeast Hsp42 directs asymmetric aggregate deposition, showing that cells can actively sequester misfolded proteins to maintain fitness (1).
• AGE‑collagen crosslinking may begin as an adaptive response to sustain tissue structure under proteostatic stress (2).
• Despite overall collagen cross‑link decline with age in mouse tendon, lysine glycation rises sharply and correlates with stiffening, suggesting failed maintenance rather than simple accumulation (3).
• AGE‑crosslinked collagen elevates microenvironment stiffness, reducing muscle progenitor proliferation via RAGE‑dependent signaling (4).
• Aging shifts the MMP/TIMP balance toward reduced proteolysis, limiting matrix remodeling (5).
• AGEs alter collagen mechanics by hindering molecular sliding, yet they do not fully explain stiffness, implicating downstream cellular responses (6).

These observations support a model where crosslinks are a compensatory layer that becomes pathological when mechanosignaling pathways suppress MMP activity.

Testable Predictions

1. In aged muscle, nuclear YAP/TAZ levels will be elevated in fibrotic regions and will correlate with TIMP1/2 expression, independent of total AGE content.
2. Genetic or pharmacological inhibition of integrin‑FAK signaling will reduce YAP/TAZ nuclear localization, lower TIMP expression, and increase MMP activity, thereby decreasing tissue stiffness even when AGE crosslinks remain high.
3. Conversely, forced expression of a constitutively active YAP isoform in young mice will recapitulate the aged MMP/TIMP imbalance and induce stiffness without increased AGE crosslinking.

Experimental Approach

• Use aged (24‑month) C57BL/6 mice and young (3‑month) controls.
• Quantify AGE‑modified collagen via ELISA and immunofluorescence; assess hydroxylysyl pyridinoline crosslinks as a secondary measure.
• Measure nuclear YAP/TAZ by subcellular fractionation and Western blot; assess TIMP1/2 and MMP‑2/‑9 mRNA and activity (gelatin zymography).
• Apply integrin‑FAK inhibitor (PF‑573228) or fibroblast‑specific FAK knockout via tamoxifen‑inducible Cre.
• Evaluate functional outcomes: ex vivo muscle force production, satellite cell proliferation (Pax7+ Ki67+), and histology for fibrosis (Sirius Red).
• Include rescue experiments where MMP‑14 is overexpressed via AAV in aged muscle to test whether restoring proteolytic capacity bypasses the YAP/TAZ‑TIMP block.

Falsifiability

If inhibiting integrin‑FAK signaling fails to reduce TIMP levels or improve stiffness despite effective blockade of YAP/TAZ nuclear translocation, the proposed feedback loop is not operative. Likewise, if MMP‑14 overexpression does not ameliorate stiffness or regeneration in the presence of high AGE crosslinks, the hypothesis that impaired remodeling—not the crosslinks themselves—drives dysfunction would be unsupported. Positive results would support the view that persistent matrix stiffness is a downstream consequence of maladaptive mechanotransmission, offering a new target for anti‑fibrotic therapies that bypass the need to remove aggregated collagen.